Pennsylvania moves closer to adopting biosimilars legislation

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Pennsylvania moves closer to adopting biosimilars legislation

Home/Policies & Legislation | Posted 29/11/2013 0 Post your comment

Pennsylvania has taken a step closer to adopting legislation which would authorize pharmacists to be able to substitute FDA-approved biosimilars for their reference biologicals, but with certain restrictions.

On 13 November 2013, the Pennsylvanian Senate Public Health and Welfare Committee voted overwhelmingly in favour of legislation known as SB 405 forbidding a pharmacist from substituting a biosimilar for a brand-name biological if a physician prohibits the substitution. The bill also requires pharmacists to notify the doctor (within 72 hours) and retain a record of the substitution.

On 12 October 2013, California Governor Jerry Brown vetoed similar legislation in California, known as SB 598, a bill that some believed would have impeded access to biosimilars [1]. Governor Brown rejected the legislation on the grounds that the bill was premature given the fact that the US Food and Drug Administration (FDA) has yet to release finalized guidance on biosimilars.

The Pennsylvania bill was passed after adding some minor amendments. One of the amendments approved by the committee reduced the length of time records on biosimilars substitutions must be retained from five to two years.

Similar bills are, or have been, contemplated in several other US states. Supporters of such bills on biosimilars substitution argue that they do not prohibit substitution, but rather protect patients. Biotech giant Amgen has stated that ‘substitution rules that strengthen communication between physician, pharmacist and patient will help accelerate the successful implementation of the US biosimilars pathway’ [2]. However, advocates for biosimilars substitution, such as the Generic Pharmaceutical Association (GPhA), say that procedures outlined in the proposed bills ‘would create red tape between patients and affordable medicines’ [3].

The Pennsylvania bill, which passed 11-0, will now go to the state Senate for a vote.

Related articles

References

1. GaBI Online - Generics and Biosimilars Initiative. California governor vetoes biosimilars bill [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 29]. Available from: www.gabionline.net/Biosimilars/News/California-governor-vetoes-biosimilars-bill

2. GaBI Online - Generics and Biosimilars Initiative. Amgen’s response to biosimilar substitution legislation in US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 29]. Available from: www.gabionline.net/Biosimilars/News/Amgen-s-response-to-biosimilar-substitution-legislation-in-US

3. GaBI Online - Generics and Biosimilars Initiative. Fourth US state rejects law restricting biosimilar substitution [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Nov 29]. Available from: www.gabionline.net/Policies-Legislation/Fourth-US-state-rejects-law-restricting-biosimilar-substitution

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Pennsylvania State Senate